Key Takeaways
This article explores how interactive demonstration spaces empower researchers to conduct side-by-side feasibility tests, such as comparing fluorescence and particle characterization for extracellular vesicles, ensuring that investments align with actual operating conditions. As equipment manufacturers shift toward consultative models, the fundamental question driving laboratory procurement is evolving from choosing an instrument to defining the core analytical problem. By prioritizing problem-solving over standard product demonstrations, lab managers can make informed decisions that bridge the gap between initial research and routine application.
Read the original article here. DiDonna, MaryBeth. "The Question Changing How Labs Choose Technology." Lab Manager, October 9, 2026.
To accelerate implementation and eliminate the pain point of misaligned capital investments, laboratories must start with an analytical question rather than a predetermined product. By collaborating with application scientists in interactive demonstration spaces like the Analytical Solution Plaza (ASP), researchers can conduct side-by-side testing of multiple methods to achieve targeted end-user outcomes.
Historically, customers approached vendors asking for specific hardware, but leaders like HORIBA Instruments Incorporated now focus on the fundamental problem the lab needs to solve. Modular carts and benches allow teams to reconfigure the space around diverse applications, supporting comprehensive testing rather than limiting evaluations to single-instrument demonstrations.
Conducting highly sensitive characterization without sample consumption requires rigorous side-by-side feasibility testing of methods like fluorescence and particle characterization. This comparative approach reveals which specific technology provides the precise scientific data necessary to meet the laboratory's Critical Quality Attributes (CQAs) before committing to a purchase.
When examining complex biological samples like extracellular vesicles, researchers rely on this testing to ensure the chosen method aligns with their exact needs. Understanding these scientific parameters helps teams determine whether a proposed instrument offers useful, actionable results before committing capital and integrating it into established workflows.
Beyond ensuring chemical purity, mitigating workflow disruption requires adapting benchtop technologies to fit actual operating conditions like sample volume and staff expertise. Integrating Quality by Design (QbD) principles early in the evaluation ensures customized setups remain viable and pave the way for successful Process Analytical Technology (PAT) adoption.
Moving from demonstration to routine use means modifying technology to fit the realities of the facility, including maintenance capacity and existing systems. For pharmaceutical research and manufacturing, clarifying vendor support and validating these workflows shapes future laboratory solutions around authentic end-user needs rather than idealized specifications.
To effectively address recurring technological limitations, laboratory managers must collaborate directly with equipment vendors to communicate unmet analytical needs and workflow challenges. Sharing these real-world operational realities enables manufacturers to design fit-for-purpose tools that accurately reflect routine laboratory environments rather than isolated benchtop conditions.
This strategic exchange benefits both parties, provided laboratories clearly establish boundaries regarding intellectual property and evaluation goals. Starting with the core problem allows teams to thoroughly compare options and validate whether a customized solution truly fits their long-term resource constraints and operational objectives.
Vous avez des questions ou des demandes ? Utilisez ce formulaire pour contacter nos spécialistes.
